Press Releases

Month Year

Month Year

Jun 2, 2022

Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab-rwlc)

Sanofi will receive an upfront payment of $900 million, and an 11% royalty on worldwide net sales of Libtayo
Jun 1, 2022

FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A

Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA
May 31, 2022

FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
May 20, 2022

FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
May 17, 2022

New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting

Data to be shared across multiple tumor types, including multiple myeloma, lung cancer and breast cancer

Show per page

Print
Email page
RSS